



Regarding completion of the Transfer of the "Mother to Mother SHIONOGI Project" the Second Phase to the Government of Kilifi County, Republic of Kenya

OSAKA, Japan, February 13, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that , it has been ongoing the "Mother to Mother SHIONOGI Project" (hereafter "this project"), a maternal and child healthcare program in Africa, and on December 31, 2023, it completed the second phase of this project in Kilifi County, the Republic of Kenya with the cooperation of the international NGO "World Vision Japan" (National Director: Mariko Kinai; hereafter "WVJ"). The Company also announces that the project was transferred to the county government.

This project is worked on improving maternal and child health with the vision of "To develop sustainable communities for the well-being of mothers and children." This will be done through collective impact*, an approach of effectively combining the strengths of respective participants, including business enterprises and NGOs. We aim not only to improve the environment for pregnancy and childbirth but also to enable community people to manage their own health by educating the local communities, helping community healthcare workers in capacity development, improving the water hygiene environment, and conducting advocacy activities toward the government.

*It maximizes the impact of the efforts by organizations including business enterprises, governments and NGOs/NPOs by their collaborative commitment to solving social issues.

The second phase focused on improving the coordination between clinics, hospitals, and government agencies in the project area. To do this, we established a system for regular coordination and guidance from higher-level health facilities and the Ministry of Health to clinic staff. This led to an improvement in maternal and child health services. Furthermore, in collaboration with Panasonic Holdings Corporation (Head Office: Osaka; Group CEO: Yuki Kusumi)¹, solar power generation systems had been installed in clinics and hospitals that lacked electricity supply, expanding the availability of medical services such as nighttime medical care. The project is currently in its third phase, which began in June 2023. The goal of this phase is to reduce diarrhea, a disease that can have a serious impact on the health of children^{2,3}.

Shionogi has identified "Improve access to healthcare" as one of the materiality (material issues) to be addressed. We are working to support mothers and children in Africa, while strengthening our partnerships with international partners. Shionogi will continue to work towards the realization of Universal Health Coverage in African region, leveraging the knowledge and networks we have gained through this project.



Rima Ra Pera Dispensary with solar panels



Handover ceremony, November 2023

Reference :

1. [Press Release on September 7, 2022](#)
Notice regarding the Beginning of Solar Power Generation at a Health Facility in Kilifi County, Kenya under the "Mother to Mother SHIONOGI Project"
2. [Press Release on June 1, 2023](#)
Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Maternal and Child Health in Kenya and Ghana
3. [Press Release on December 22, 2023](#)
Signing of Collaboration Agreement in the Third Phase of the "Mother to Mother SHIONOGI Project" - App Development for Diarrhea Prevention in Tanzania -

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>